An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia - Test2 - elhamkhani - TriplyDB

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia

http://www.wikidata.org/entity/Q34197535

about

A scalable method for molecular network reconstruction identifies properties of targets and mutations in acute myeloid leukemia Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.A framework for regularized non-negative matrix factorization, with application to the analysis of gene expression data Pre-clinical drug prioritization via prognosis-guided genetic interaction networks Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia.Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia Investigating the prediction ability of survival models based on both clinical and omics data: two case studies.Deviance residuals-based sparse PLS and sparse kernel PLS regression for censored data.Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis.PrognoScan: a new database for meta-analysis of the prognostic value of genes.Quantitative comparison of microarray experiments with published leukemia related gene expression signatures.The use of knockout mice reveals a synergistic role of the Vav1 and Rasgrf2 gene deficiencies in lymphomagenesis and metastasis Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.A differentiation-based phylogeny of cancer subtypes.Higher HOPX expression is associated with distinct clinical and biological features and predicts poor prognosis in de novo acute myeloid leukemia Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells.Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.Spectral clustering using Nyström approximation for the accurate identification of cancer molecular subtypes Identifying the gene signatures from gene-pathway bipartite network guarantees the robust model performance on predicting the cancer prognosis.A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis.Transformation resistance in a premature aging disorder identifies a tumor-protective function of BRD4.Molecular signatures in acute myeloid leukemia.Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells.Engagement of SIRPα inhibits growth and induces programmed cell death in acute myeloid leukemia cells.Integrative genomic analyses of a novel cytokine, interleukin-34 and its potential role in cancer prediction.Added predictive value of omics data: specific issues related to validation illustrated by two case studies.Sparse expression bases in cancer reveal tumor drivers.Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia Hierarchy in gene expression is predictive of risk, progression, and outcome in adult acute myeloid leukemia Systematic computation with functional gene-sets among leukemic and hematopoietic stem cells reveals a favorable prognostic signature for acute myeloid leukemia An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.Sox4 cooperates with PU.1 haploinsufficiency in murine myeloid leukemia.PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway.Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia FHL2 interacts with CALM and is highly expressed in acute erythroid leukemia.High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.Functional analysis of the NUP98-CCDC28A fusion protein.The aryl hydrocarbon receptor pathway: a key component of the microRNA-mediated AML signalisome.

P2860

Q24289222-2665A4B3-436D-4C3B-88CD-93DFAE191089 Q24597256-287FB73D-4288-458C-A4BA-15B7FBAF6B95 Q27851694-B594B737-78C1-4FF5-80FF-041BB3BE6E92 Q28278807-686CD6CE-E36A-4289-9423-112769F9EFFE Q28476072-EC30A5D6-66A9-41E3-BE5E-868D1669AED3 Q30490446-310A02F8-A283-4F3E-A7AA-0BA398E73EBE Q30608477-7F6F4F99-0D21-4AC0-8FAC-0652950082ED Q30837398-0608188C-EE2A-435B-B36E-C710232853DB Q30857702-7824C411-2052-4951-99FC-BFF5F9776753 Q30975629-2B388B18-66E8-48C5-A012-3E36B5704E90 Q33434943-12DAA909-6104-4A76-B661-79008FDEFAEE Q33518038-138E6BBA-F996-4537-89D6-9A33724FF326 Q33518516-6B28BE9C-5FA3-43D6-9261-9A03DEAB115F Q33555627-2947F8D3-2DFA-4020-847E-B5FACEE8D402 Q33576721-D83FD759-8DE6-46DA-8B54-A3968842E31D Q33746724-F6BA334D-6342-40F5-86C3-544DC72B4C3A Q33758623-D6EACEC3-34E1-48D4-B8AA-3F53B150FE40 Q33873844-6EB86063-5C2C-4F1D-90B4-A4E7640BAC43 Q33884798-641D353E-A392-413B-A243-74837DA093F0 Q34003648-4C1CE5D7-D2EF-49DB-A6FE-10EBF99C0A1D Q34221688-18529286-692E-471C-BE90-0E1A4E8276E9 Q34324403-A9A4DEAA-3B15-47AC-8180-1F992A5B4CD9 Q34403639-3CF9A7D8-C1E8-4F2A-AD7B-EE4F2C1911D2 Q34421127-86E037D8-5C5B-47BE-BDC1-8D94037D89DC Q34548156-710285B7-6FEF-461B-9279-79A2F95C8DB8 Q34599064-EB1BDE70-C4FA-4307-B19C-330F6749302C Q34738967-E7F0A3F5-5633-40A7-A874-8E9D5C3E445B Q35088941-E275958A-691B-4B36-BDC1-95B3730D46D1 Q35152173-8B4B5137-2323-4A68-ADA6-FFE9E0515FC9 Q35170920-C1242341-4413-4F8C-86C9-43EC3DDE349A Q35223635-9AA0F3FF-FEF8-42C6-B10A-4EAA9B8D1823 Q35237394-640FFA4B-44F9-49AE-A820-3D6CF51F866F Q35525433-6C377364-ECA0-47DF-A0CC-763417342BB3 Q35541213-8057F9E4-EC3C-4049-AB60-D233ABB50CF6 Q35638335-39D5C301-2EF6-40C2-A4F6-13D05FA1DA96 Q35668394-C485256E-07B8-4153-A38C-32C5EED67516 Q35741669-1FD91C37-AB2F-4E18-88B3-C269DD342B16 Q35781530-CC509A0F-3B17-4E4C-BF77-B3DCB26DD726 Q35794430-88822542-E2D6-4D16-A81C-F709B6EB7A31 Q36067630-1B27C453-20FD-4E2D-A22C-4DA61F0D105F

P2860

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia

http://www.wikidata.org/entity/Q34197535

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

An 86-probe-set gene-expressio ...... normal acute myeloid leukemia

@ast

An 86-probe-set gene-expressio ...... normal acute myeloid leukemia

@en

An 86-probe-set gene-expressio ...... normal acute myeloid leukemia

@nl

type

label

An 86-probe-set gene-expressio ...... normal acute myeloid leukemia

@ast

An 86-probe-set gene-expressio ...... normal acute myeloid leukemia

@en

An 86-probe-set gene-expressio ...... normal acute myeloid leukemia

@nl

prefLabel

An 86-probe-set gene-expressio ...... normal acute myeloid leukemia

@ast

An 86-probe-set gene-expressio ...... normal acute myeloid leukemia

@en

An 86-probe-set gene-expressio ...... normal acute myeloid leukemia

@nl

P1433

Q34197535-F3C23194-CE7A-4475-A226-2EC88D0AE4A9

P1476

Q34197535-02315604-F2B8-45C2-BB95-9E937629B113

P2093

Q34197535-066A267F-7C90-4B22-BA33-B0EE95A35B6B

Q34197535-0C952165-0223-477B-A01A-F085EDA90BCB

Q34197535-0D18DFF2-978C-4DE7-B676-98954400D6E8

Q34197535-1AC2F16E-BFE9-4D04-82CF-9DAFD15C39C5

Q34197535-25EE273C-0536-48C6-AB68-C29597B05B31

Q34197535-34F74C10-4A7B-4D7B-B6F5-3AD2ECF40AF5

Q34197535-39C90CB9-0C3B-4A9D-BD19-BEB337DA95CB

Q34197535-812B4FF1-6491-4001-832E-06E1A1D63E35

Q34197535-882E6067-977A-49C5-ABB2-6A5AB8A6CD0B

Q34197535-97EC98FB-97AF-446E-AB26-DFA6DA98537F

P2860

Q34197535-0DF78EA5-5314-4ADC-92B4-E8B62E31E064

Q34197535-114CAF63-AB10-4617-B205-A334E5812349

Q34197535-133C84E0-BAC0-4AD3-82C4-9F284D4680A7

Q34197535-19180836-D3CB-4C69-B23D-19BFBD903142

Q34197535-27C7BE33-E4FD-49B7-9D6F-D2E5ECE30646

Q34197535-329E7E30-F167-4541-B967-C9259A0F1219

Q34197535-3842238A-FA89-4407-BC83-1BA09362CD0D

Q34197535-3CFD8D3D-79B4-4271-ADD2-7024916B760A

Q34197535-420ECA36-A348-4641-926E-0EFFB871B92C

Q34197535-65E2B635-A696-4115-8C24-A9C228E24373

P304

Q34197535-0F079402-9688-4EA6-B99F-6AAFB4F40598

P31

Q34197535-662C224B-7CC2-4513-A222-86083C87ADD2

P356

Q34197535-82998A7B-6528-4F65-AB5A-9978E485A3C2

P407

Q34197535-2E56762E-58F8-48E0-B586-688E3C01723E

P433

Q34197535-F081D42D-B3CA-482B-945B-B6E0DA27AE73

P478

Q34197535-D08C06CB-59E5-4129-9EDF-547C3C84AD7B

P50

Q34197535-23A5B143-1C42-45CA-8617-D1F725EE8CBD

Q34197535-24DB012B-4EC8-4E41-A1D3-CCF74904AF04

Q34197535-411AC630-8A44-4967-BDED-C8FFE2C071FB

Q34197535-4D79256A-D52D-43A9-8061-BF9AAFF3D4C5

Q34197535-D234A9DC-9E43-40AD-B65A-3234A88451D6

Q34197535-D90AFD12-7CE8-408F-B153-E2A5B18D1787

Q34197535-FEFEFCD8-705B-4F94-9D1C-50A4A4CF1DC8

P577

Q34197535-4DD6E7F8-F604-4640-9004-74144754A42C

P5875

Q34197535-E8B8B16B-FDA0-4ED5-8973-EB9B6619D86C

P698

Q34197535-183D3311-890D-4980-9C29-3A4D0FAFC2D8

P921

Q34197535-C1240F5A-A1AF-469D-95A2-9B8D016E7E43

P932

Q34197535-EAA706AF-7051-42DA-8BFE-1F8702C17669

P356

BLOOD-2008-02-134411

P1433

P1476

An 86-probe-set gene-expressio ...... normal acute myeloid leukemia

@en

P2093

Achim Heinecke

http://www.w3.org/2001/XMLSchema#string

Bernhard Wörmann

http://www.w3.org/2001/XMLSchema#string

Christian Buske

http://www.w3.org/2001/XMLSchema#string

German AML Cooperative Group

http://www.w3.org/2001/XMLSchema#string

Jan Braess

http://www.w3.org/2001/XMLSchema#string

Karsten Spiekermann

http://www.w3.org/2001/XMLSchema#string

Manuela Hummel

http://www.w3.org/2001/XMLSchema#string

Maria-Cristina Sauerland

http://www.w3.org/2001/XMLSchema#string

Michael Radmacher

http://www.w3.org/2001/XMLSchema#string

Peter Paschka

http://www.w3.org/2001/XMLSchema#string

P2860

Bioconductor: open software development for computational biology and bioinformatics

Semi-supervised methods to predict patient survival from gene expression data

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

Variance stabilization applied to microarray data calibration and to the quantification of differential expression

P304

4193-4201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-02-134411

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

Klaus H Metzeler

Stefan K. Bohlander

Richard A. Larson

Clara D. Bloomfield

Cancer and Leukemia Group B

P577

2008-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23183342

http://www.w3.org/2001/XMLSchema#string

P698

18716133

http://www.w3.org/2001/XMLSchema#string

P921

P932

2954679

http://www.w3.org/2001/XMLSchema#string